Acute Repetitive Seizures Market Size, Share & Trends Analysis Report By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region (U.S., U.K., Canada, Germany), And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope and Assumptions
1.3 List to Data Sources
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Acute Repetitive Seizures Market
3.3 Market Driver Analysis
3.3.1 Presence of strong pipeline and increasing initiatives for R&D
3.3.2 Presence of treatment gap in adequate seizure control
3.3.3 Other drivers
3.4 Market restraint Analysis
3.4.1 Cost of treatment
3.5插入映射
3.6 Caregiver’s perception on route of administration
3.7 Importance of having no sedation as a side effect
3.8 Opportunity Analysis
Chapter 4 Acute Repetitive Seizures: Product Outlook
4.1 Acute repetitive seizures Market: Product Movement Analysis
4.2 USL-261
4.2.1 USL-261 market, 2013 - 2025 (USD Million)
4.3 NRL-1
4.3.1 NRL-1 market, 2013 - 2025 (USD Million)
4.4 AZ-002
4.4.1 AZ-002 market, 2013 - 2025 (USD Million)
4.5 Diastat直肠凝胶
4.5.1 Diastat Rectal Gel market, 2013 - 2025 (USD Million)
4.6 Others
4.6.1 Other acute repetitive seizures market, 2013 - 2025 (USD Million
Chapter 5 Acute repetitive seizures Market: Regional Estimates & Trend Analysis
5.1 Acute repetitive seizures market share by region, 2016 & 2025
5.2 North America
5.2.1 North America acute repetitve seizures market, 2013 - 2025 (USD Million)
5.2.1.1 U.S.
5.2.1.2 U.S. acute repetitve seizures market, 2013 - 2025 (USD Million)
5.2.1.2 Canada
5.2.1.2 Canada acute repetitve seizures market, 2013 - 2025 (USD Million)
5.3 Europe
5.3.1 Europe acute repetitve seizures market, 2013 - 2025 (USD Million)
5.3.1.1 Germany
5.3.1.2 Germany acute repetitve seizures market, 2013 - 2025 (USD Million)
5.3.1.3 U.K.
5.3.1.4 U.K. acute repetitve seizures market, 2013 - 2025 (USD Million)
5.4 Rest of World
5.4.1 Rest of World acute repetitve seizures market, 2013 - 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Company Profiles
6.2.1 UCB S.A. Belgium
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Product benchmarking
6.2.1.4 Strategic initiatives
6.2.2 Neurelis
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Product benchmarking
6.2.2.4 Strategic initiatives
6.2.3 Valeant Pharmaceuticals North America LLC.
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Product benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Alexza Pharmaceuticals
6.2.4.1 Company overview
6.2.4.2 Product benchmarking
6.2.4.3 Strategic initiatives
6.2.5 VERITON PHARMA
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Product benchmarking
6.2.5.4 Strategic initiatives

List of Tables

Table 1 Acute Repetitive Seizures Pipeline, 2018
Table 2 Country share estimation
Table 3 North America acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
Table 4 U.S. acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
Table 5 Canada acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
Table 6 Europe acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
Table 7 Germany acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
Table 8 U.K. acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
Table 9 Rest of World acute repetitive seizures market, by product, 2013 - 2025 (USD Million)

数据列表

Fig. 1 Market summary
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Value chain-based sizing & forecasting
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market trends & outlook
Fig. 7 Market segmentation & scope
Fig. 8 Global acute repetitive seizures market, 2013 - 2025 (USD Million)
Fig. 9 Market driver relevance analysis (Current & future impact)
Fig. 10 Market restrain relevance analysis (Current & future impact)
Fig. 11 Penetration & growth prospect mapping
Fig. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Acute repetitive seizures market product outlook key takeaways
Fig. 15 Acute repetitive seizures market: Product movement analysis
Fig. 16 Global USL-261 market, 2013 - 2025 (USD Million)
Fig. 17 Global Neurelis-1 market, 2013 - 2025 (USD million)
Fig. 18 Global AZ-002 market, 2013 - 2025 (USD Million)
Fig. 19 Global diastat rectal gel market, 2013 - 2025 (USD Million)
Fig. 20 Others market, 2013 - 2025 (USD Million)
Fig. 21 Regional market place: Key takeaways
Fig. 22 Acute repetitive seizures market: Regional movement analysis
Fig. 23 North America acute repetitive seizures market, 2013 - 2025 (USD Million)
Fig. 24 U.S. acute repetitive seizures market, 2013 - 2025 (USD Million)
Fig. 25 Canada acute repetitive seizures market, 2013 - 2025 (USD Million)
Fig. 26 Europe acute repetitive seizures market, 2013 - 2025 (USD Million)
Fig. 27 Germany acute repetitive seizures market, 2013- 2025 (USD Million)
Fig. 28 U.K. acute repetitive seizures market, 2013 - 2025 (USD Million)
Fig. 29 Rest of World acute repetitive seizures market, 2013 - 2025 (USD Million)
Fig. 30 Strategy framework